BCM
AVTX icon

Bridgeway Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Bridgeway Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-90
Closed -$1.11M – 1416
2018
Q1 		$1.11M Hold
90
– – 0.01% 810
2017
Q4 		$826K Buy
+90
New +$388K 0.01% 915

Other funds holding AVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
DBIA
Dumont & Blake Investment Advisors Princeton, New Jersey $445M AUM 31.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Bridgeway Capital Management's AVTX Position: Q2 2018 in Review

Bridgeway Capital Management sold out of Avalo Therapeutics (AVTX) in Q2 2018, closing a stake of 90 shares — an estimated $1.11M sold.

Bridgeway Capital Management first reported a position in AVTX in Q4 2017 and held it in 2 quarters. The position peaked at $1.11M in Q1 2018. 18 funds tracked by Wall St. Rank hold AVTX as of Q2 2018.

  • Bridgeway Capital Management reported no remaining Avalo Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Bridgeway Capital Management sold 90 Avalo Therapeutics shares in Q2 2018, an estimated $1.11M.
  • Bridgeway Capital Management first reported a position in Avalo Therapeutics in Q4 2017 and held it in 2 quarters.
  • Bridgeway Capital Management's Avalo Therapeutics position peaked at $1.11M in Q1 2018.
  • 18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2018.

Based on Bridgeway Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.